Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

2.2K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.2K
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

432
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
432
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

2.6K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.6K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

1.4K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.4K
Pharmaceutical Poisoning: Potential Scenarios01:26

Pharmaceutical Poisoning: Potential Scenarios

47
Pharmaceutical poisoning can occur through various channels, impacting an estimated 2 million hospitalized patients in the U.S. annually with serious adverse drug responses. These scenarios encompass both therapeutic uses, such as drug toxicity, where even standard dosages can lead to severe central nervous system depression, and non-therapeutic exposures, including accidental ingestion by children, and environmental and occupational exposures.Unintentional poisonings often involve exploratory...
47
Drug Control Governance: Regulatory Bodies and Their Impact01:03

Drug Control Governance: Regulatory Bodies and Their Impact

629
Drug control governance involves the oversight and regulation of pharmaceuticals to ensure their safety and efficacy while preventing illegal drug use and trafficking. Regulatory bodies, including the US Food and Drug Administration (FDA) and the European Union's European Medicines Agency (EMA), play a central role in this process. These agencies evaluate the safety and efficacy of drugs before they can be marketed. They fund clinical trials and assess the benefits and risks associated with...
629

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Should we focus on sustainable thromboprophylaxis and avoid overuse of low-molecular-weight heparins?

Research and practice in thrombosis and haemostasis·2026
Same author

Explainable, Generative and Agentic Artificial Intelligence for the Peripheral Blood Film.

International journal of laboratory hematology·2026
Same author

Artificial intelligence triage tool for bone marrow fibrosis in myeloproliferative neoplasms using complete blood counts.

The Lancet. Haematology·2026
Same author

Platelets must not be overlooked in civilian and military blood preparedness.

Lancet (London, England)·2026
Same author

Two Unusual Cases of Thrombotic Microangiopathies.

Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion·2026
Same author

Monitoring Hemostatic Function During Extracorporeal Membrane Oxygenation with Point-of-Care Viscoelastic Assays: A Narrative Review.

Seminars in thrombosis and hemostasis·2026

Related Experiment Video

Updated: Mar 8, 2026

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood
11:17

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood

Published on: October 12, 2012

14.5K

Safeguarding global anticoagulant supply and access.

Bingwen Eugene Fan1, Jacques Kah Yee Tang2, Emmanuel J Favaloro3

  • 1Department of Haematology, Tan Tock Seng Hospital, Singapore; KLARIS Precision Health Research Clinic, Tan Tock Seng Hospital, Singapore; Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore; Department of Haematology, Northern Health, Epping, Victoria, Australia; Yong Loo Lin School of Medicine, National University of Singapore, Singapore.

Journal of Thrombosis and Haemostasis : JTH
|March 6, 2026
PubMed
Summary

Global anticoagulant supply chains are fragile, risking shortages during crises. Building resilience requires developing non-animal alternatives and diversifying production for reliable access to these essential medicines.

Keywords:
anticoagulantsdrug shortagesheparinsupply chain managementwarfarin

More Related Videos

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke
09:21

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke

Published on: January 18, 2018

12.7K
Multiplex Therapeutic Drug Monitoring by Isotope-dilution HPLC-MS/MS of Antibiotics in Critical Illnesses
11:17

Multiplex Therapeutic Drug Monitoring by Isotope-dilution HPLC-MS/MS of Antibiotics in Critical Illnesses

Published on: August 30, 2018

13.5K

Related Experiment Videos

Last Updated: Mar 8, 2026

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood
11:17

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood

Published on: October 12, 2012

14.5K
Optimized Management of Endovascular Treatment for Acute Ischemic Stroke
09:21

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke

Published on: January 18, 2018

12.7K
Multiplex Therapeutic Drug Monitoring by Isotope-dilution HPLC-MS/MS of Antibiotics in Critical Illnesses
11:17

Multiplex Therapeutic Drug Monitoring by Isotope-dilution HPLC-MS/MS of Antibiotics in Critical Illnesses

Published on: August 30, 2018

13.5K

Area of Science:

  • Pharmacology and Global Health Security

Background:

  • Anticoagulants are critical medical supplies with inherently fragile global supply chains.
  • Reliance on animal-derived heparin and synthetic alternatives (e.g., warfarin, DOACs) presents risks from contamination, disease, manufacturing, and geopolitical factors.
  • The COVID-19 pandemic highlighted the vulnerability of anticoagulant access during global crises.

Purpose of the Study:

  • To analyze the vulnerabilities in the global anticoagulant supply chain.
  • To propose strategies for enhancing the resilience and reliability of anticoagulant access.
  • To advocate for anticoagulants as essential medical assets requiring international coordination.

Main Methods:

  • Review of existing literature on anticoagulant supply chains.
  • Analysis of risks associated with animal-derived and synthetic anticoagulants.
  • Identification of systemic vulnerabilities exposed by recent global events.
  • Formulation of recommendations for supply chain resilience.

Main Results:

  • Current anticoagulant supply chains are susceptible to disruptions from animal-source issues, manufacturing challenges, and geopolitical instability.
  • These vulnerabilities can lead to critical shortages, as evidenced during the COVID-19 pandemic.
  • A systemic approach is needed to mitigate these risks.

Conclusions:

  • Developing non-animal-derived anticoagulants is crucial for supply chain resilience.
  • Geographic diversification of production, protected supply corridors, and reduced manufacturing footprints are necessary.
  • Equitable allocation frameworks and sustained international investment are vital to ensure reliable global access to anticoagulants.